Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
Abstact
Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.
Protocols
One protocol is associated with this publication:
Authors
- Adam BL
- Bigbee WL
- Carroll C
- Conrads TP
- Feng Z
- Grizzle WE
- Izbicka E
- Jendoubi M
- Johnsey D
- Kagan J
- Leach RJ
- McCarthy DB
- Semmes OJ
- Srivastava S
- Srivastava S
- Thompson IM
- Thornquist MD
- Verma M
- Zhang Z
- Zou Z